Immunocore

By taking part in clinical trials, patients can make an important contribution to ongoing research and better understanding of a disease. Clinical trials are also an opportunity to be a part of testing a potential new therapy.

The company provides an information page for healthcare professionals based in the US.

The company has one approved medication on the market and late-stage and pre-clinical programs in its pipeline.

The company’s pipeline includes clinical-stage programs in oncology and infectious diseases, as well as pre-clinical projects.

The human immune system is designed to protect the body from disease, without damaging healthy cells.

The immune system is a sophisticated network of cells and molecules that protect the body against infections and other diseases. It consists of two main branches: innate immunity and adaptive immunity.

Bispecific molecules are a growing category of immunotherapy that work by forming a direct connection between the immune system and a cell that the bispecific therapy should kill or protect.

Please fill out the form below to receive company press releases via email when they occur.

No upcoming events are currently scheduled. The page offers notices about upcoming events and press releases.

Immunocore announced it achieved target enrollment in the registrational TEBE-AM trial of KIMMTRAK (tebentafusp) in previously treated patients.

Immunocore planned to present at upcoming investor conferences in Oxfordshire, England; Radnor, PA; and Gaithersburg, MD, US, on 1 September.

Professor Sir John Bell joined Immunocore’s board in March 2015. He is Regius Professor of Medicine at Oxford University, chairs the Office for the Strategic Coordination of Health Research, and has experience in genomics, genetics, immunology, and healthcare.

The company has assembled a team with R&D experience to develop next-generation immunotherapies.

Dr Bahija Jallal is CEO and director of Immunocore’s board. Before joining Immunocore in January 2019, she was president of MedImmune, AstraZeneca’s global biologics research and development unit, and executive vice president of AstraZeneca.

Immunocore is a commercial-stage biotechnology company that discovered, developed and commercialized the world’s first approved T cell receptor (TCR) therapy.

Immunocore Ltd says it is committed to lawful and ethical operations and to following applicable laws, regulations, and codes in the countries where it operates. The company identifies integrity and transparency as central to maintaining trust with its stakeholders.

Chemistry, Manufacturing and Controls, or CMC, is a critical function in drug development. But it is sometimes misunderstood as a formality after the discovery of a potential new treatment.

The company aims to improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases through immunomodulating medicines.

The company says its statements are opinions subject to change and disclaims liability for readers’ or subscribers’ investment decisions.